IL ‐17, IL ‐23, and IL ‐36α Expression in Palmoplantar Psoriasis, Palmoplantar Eczema, and Plaque Psoriasis: Implications on Diagnosis and Treatment Selection
Journal of Cutaneous Pathology · 2026-07 · 53 (7) · 633-639
DOI: 10.1111/cup.70100 ↗At a glance
Journal article in Journal of Cutaneous Pathology, published online on 2026-03-30. Written by Şeyma Kaya Bulut and 7 co-authors. Institution: Department of Dermatology, Necmettin Erbakan University Medical Faculty, Konya, Turkey. Major MEDLINE topics: Psoriasis, Interleukin-17, Interleukin-1, Eczema. 21 references. Funded by: Necmettin Erbakan University Scientific Research Foundation (BAP).
Abstract (original language)
Background
Palmoplantar psoriasis exhibits greater treatment resistance compared to other psoriatic plaques and presents clinical and histopathological overlap with palmoplantar eczema. This study aimed to investigate treatment resistance mechanisms in palmoplantar psoriasis and assess the contribution of IL‐17, IL‐23, and IL‐36α to the differential diagnosis of palmoplantar psoriasis and eczema. Immunohistochemical levels of these cytokines were measured in paired acral and non‐acral psoriatic samples.
Methods
We retrospectively included 73 patients: 25 with only palmoplantar psoriasis, 25 with palmoplantar eczema, and 23 with both conditions and concurrent plaque psoriasis. Clinical and histopathological diagnoses were confirmed. Immunohistochemical analyses were conducted using preparations stained for IL‐17, IL‐23, and IL‐36α.
Results
In psoriasis cases, immunohistochemical examination of biopsies from both body and palmoplantar regions showed lower IL‐17 and IL‐36α expression in acral regions compared to non‐acral regions. In palmoplantar eczema patients, IL‐17 and IL‐23 expression was higher than in palmoplantar psoriasis patients; however, IL‐36α expression was similar in both conditions.
Conclusions
The diminished expression of IL‐17 and IL‐36α in palmoplantar psoriasis compared to other body sites may contribute to variable responses to targeted treatments. These findings suggest the potential for developing distinct biological treatments for these regions.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Dermatology, Necmettin Erbakan University Medical Faculty, Konya, Turkey.
- Department of Pathology, Necmettin Erbakan University Medical Faculty, Konya, Turkey.
- Department of Public Health, Necmettin Erbakan University Medical Faculty, Konya, Turkey.
ORCID profiles: Şeyma Kaya Bulut, Recep Dursun, Sıdıka Fındık, Selami Aykut Temiz, Mehmet Uyar, Munise Daye, İlkay Özer, Havvanur Çalışkan
Funding
- Necmettin Erbakan University Scientific Research Foundation (BAP)
Cite
APA
Bulut, Ş. K., Dursun, R., Fındık, S., Temiz, S. A., Uyar, M., Daye, M., Özer, İ., & Çalışkan, H. (2026). IL ‐17, IL ‐23, and IL ‐36α Expression in Palmoplantar Psoriasis, Palmoplantar Eczema, and Plaque Psoriasis: Implications on Diagnosis and Treatment Selection. Journal of Cutaneous Pathology, 53(7), 633-639. https://doi.org/10.1111/cup.70100
Vancouver
Bulut ŞK, Dursun R, Fındık S, Temiz SA, Uyar M, Daye M, et al. IL ‐17, IL ‐23, and IL ‐36α Expression in Palmoplantar Psoriasis, Palmoplantar Eczema, and Plaque Psoriasis: Implications on Diagnosis and Treatment Selection. Journal of Cutaneous Pathology. 2026;53(7):633-639. doi:10.1111/cup.70100
BibTeX
@article{Bulut2026,
author = {Bulut, Şeyma Kaya and Dursun, Recep and Fındık, Sıdıka and Temiz, Selami Aykut and Uyar, Mehmet and Daye, Munise and Özer, İlkay and Çalışkan, Havvanur},
title = {IL ‐17, IL ‐23, and IL ‐36α Expression in Palmoplantar Psoriasis, Palmoplantar Eczema, and Plaque Psoriasis: Implications on Diagnosis and Treatment Selection},
journal = {Journal of Cutaneous Pathology},
year = {2026},
volume = {53},
number = {7},
pages = {633--639},
doi = {10.1111/cup.70100}
}
EUVIMED